Biotherapeutics and immunogenicity: ophthalmic perspective.
作者信息
Sharma Ashish, Kumar Nilesh, Kuppermann Baruch D, Bandello Francesco, Loewenstein Anat
机构信息
Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India.
Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA.
出版信息
Eye (Lond). 2019 Sep;33(9):1359-1361. doi: 10.1038/s41433-019-0434-y. Epub 2019 Apr 9.
Abstract
摘要
相似文献
1
Biotherapeutics and immunogenicity: ophthalmic perspective.生物疗法与免疫原性：眼科视角
Eye (Lond). 2019 Sep;33(9):1359-1361. doi: 10.1038/s41433-019-0434-y. Epub 2019 Apr 9.
2
Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space.深入了解眼内空间中生物疗法的免疫原性。
AAPS J. 2017 Nov;19(6):1656-1668. doi: 10.1208/s12248-017-0128-y. Epub 2017 Aug 9.
3
immunogenicity prediction: bridging between innate and adaptive immunity.免疫原性预测：固有免疫与适应性免疫之间的桥梁。
Bioanalysis. 2021 Jul;13(13):1071-1081. doi: 10.4155/bio-2021-0077. Epub 2021 Jun 14.
4
Determinants of immunogenic response to protein therapeutics.蛋白质治疗药物免疫原性反应的决定因素。
Biologicals. 2012 Sep;40(5):364-8. doi: 10.1016/j.biologicals.2012.06.001. Epub 2012 Jul 5.
5
Immunogenicity of biotherapeutics: a need for consensus on flexibility of approach.生物治疗药物的免疫原性：需要就方法的灵活性达成共识。
Curr Drug Saf. 2010 Oct;5(4):272-4. doi: 10.2174/157488610792245975.
6
Use of piromen in ophthalmology.吡咯烷酮在眼科中的应用。
Bol Asoc Med P R. 1956 Sep;48(9):372-88.
7
Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.关于多结构域生物治疗药物免疫原性反应特征描述的建议。
J Immunol Methods. 2014 Jun;408:1-12. doi: 10.1016/j.jim.2014.05.010. Epub 2014 May 24.
8
Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters.生物类似药和生物改良药开发背景下的生物治疗药物的免疫原性。
Drug Discov Today. 2011 Apr;16(7-8):345-53. doi: 10.1016/j.drudis.2011.01.011. Epub 2011 Feb 12.
9
Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab.以乌司奴单抗为例的生物治疗的免疫原性检测方法的开发和验证。
Clin Exp Immunol. 2019 May;196(2):259-275. doi: 10.1111/cei.13261. Epub 2019 Feb 3.
10
A European perspective on immunogenicity evaluation.欧洲对免疫原性评估的观点。
Nat Biotechnol. 2009 Jun;27(6):507-8. doi: 10.1038/nbt0609-507.
引用本文的文献
1
Aflibercept 2 mg biosimilar (Tyalia)-real-world experience from IRAN (ATRIA study).阿柏西普2毫克生物类似药（Tyalia）——来自伊朗的真实世界经验（ATRIA研究）
Eye (Lond). 2025 May 3. doi: 10.1038/s41433-025-03813-2.
2
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study.生物类似药雷珠单抗（Ranieyes）在现实世界中的安全性和有效性：BRESER研究
J Vitreoretin Dis. 2025 Feb 27:24741264251322213. doi: 10.1177/24741264251322213.
3
Prediction of adverse drug reactions using demographic and non-clinical drug characteristics in FAERS data.利用 FAERS 数据中的人口统计学和非临床药物特征预测药物不良反应。
Sci Rep. 2024 Oct 9;14(1):23636. doi: 10.1038/s41598-024-74505-2.
4
Structure-Based Design of Peptides Targeting VEGF/VEGFRs.靶向血管内皮生长因子/血管内皮生长因子受体的肽的基于结构的设计
Pharmaceuticals (Basel). 2023 Jun 7;16(6):851. doi: 10.3390/ph16060851.
5
Fear of safety compromise with biosimilar anti-VEGF-perception or truth.对生物类似药抗VEGF安全性受损的担忧——认知还是事实。
Eye (Lond). 2022 Nov;36(11):2086-2087. doi: 10.1038/s41433-022-02117-z. Epub 2022 May 26.
6
Ranizurel safety evaluation in real-world -(RaSER) study.雷尼祖尔在现实世界中的安全性评估 - （RaSER）研究
Am J Ophthalmol Case Rep. 2022 Feb 2;25:101358. doi: 10.1016/j.ajoc.2022.101358. eCollection 2022 Mar.
7
Future of anti-VEGF: biosimilars and biobetters.抗血管内皮生长因子药物的未来：生物仿制药和生物改良药。
Int J Retina Vitreous. 2022 Jan 4;8(1):2. doi: 10.1186/s40942-021-00343-3.
8
Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases.玻璃体内注射雷珠单抗生物类似药（Razumab）治疗脉络膜视网膜疾病的真实世界安全性结果
Ophthalmol Ther. 2021 Jun;10(2):337-348. doi: 10.1007/s40123-021-00345-2. Epub 2021 Apr 17.
9
Medication-induced Uveitis: An Update.药物性葡萄膜炎：最新进展
J Ophthalmic Vis Res. 2021 Jan 20;16(1):84-92. doi: 10.18502/jovr.v16i1.8254. eCollection 2021 Jan-Mar.
10
The Development Pathway for Biosimilar Biotherapeutics.生物类似药生物治疗剂的开发途径。
J Ophthalmic Vis Res. 2020 Aug 6;15(3):273-274. doi: 10.18502/jovr.v15i3.7444. eCollection 2020 Jul-Sep.
本文引用的文献
1
Comparative immunogenicity assessment of biosimilars.生物类似药的免疫原性比较评估。
Future Oncol. 2019 Jan;15(3):319-329. doi: 10.2217/fon-2018-0553. Epub 2018 Oct 3.
2
Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis.接受玻璃体内抗血管内皮生长因子注射患者的眼内炎发生率：一项美国索赔分析。
Clin Ophthalmol. 2018 Aug 30;12:1625-1635. doi: 10.2147/OPTH.S169143. eCollection 2018.
3
Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection.玻璃体内注射后眼内液中治疗性抗体的免疫原性检测。
Bioanalysis. 2018 Jun 1;10(11):803-814. doi: 10.4155/bio-2018-0047. Epub 2018 Apr 11.
4
The Immunogenicity of Biologic Therapies.生物疗法的免疫原性。
Curr Probl Dermatol. 2018;53:37-48. doi: 10.1159/000478077. Epub 2017 Nov 7.
5
How the immune system responds to therapeutic biological agents.免疫系统如何对治疗性生物制剂作出反应。
J Int Med Res. 2016 Sep;44(1 suppl):38-42. doi: 10.1177/0300060515593248.
6
Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist.对生物制剂的超敏反应和免疫反应：过敏症专科医生面临的机遇
Ann Allergy Asthma Immunol. 2016 Aug;117(2):115-20. doi: 10.1016/j.anai.2016.05.013.
7
Assessing the Immunogenicity of Biopharmaceuticals.评估生物制药的免疫原性。
BioDrugs. 2016 Jun;30(3):195-206. doi: 10.1007/s40259-016-0174-5.
8
Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.雷珠单抗或阿柏西普注射治疗年龄相关性黄斑变性后发生的严重眼部炎症：一项回顾性索赔数据库分析
Ophthalmic Epidemiol. 2016;23(2):71-9. doi: 10.3109/09286586.2015.1090004. Epub 2016 Feb 8.
9
Anti-VEGF drugs in the prevention of blindness.抗血管内皮生长因子药物在预防失明中的应用
Community Eye Health. 2014;27(87):44-6.
10
Potential Sources and Roles of Adaptive Immunity in Age-Related Macular Degeneration: Shall We Rename AMD into Autoimmune Macular Disease?适应性免疫在年龄相关性黄斑变性中的潜在来源及作用：我们是否应将年龄相关性黄斑变性重新命名为自身免疫性黄斑疾病？
Autoimmune Dis. 2014;2014:532487. doi: 10.1155/2014/532487. Epub 2014 Apr 30.
Zotero 插件